Insulin aspart
- Generic Name
- Insulin aspart
- Brand Names
- Fiasp, Novolog, Novolog Mix, Novomix, Novorapid, Novorapid Penfill, Ryzodeg, Truvelog Mix 30, Kirsty (previously Kixelle), NovoRapid, Insulin aspart Sanofi, NovoMix
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 116094-23-6
- Unique Ingredient Identifier
- D933668QVX
- Background
Insulin aspart is a rapid-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Insulin is typically prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the pancreas that promotes glucose metabolism. Insulin ...
- Indication
Insulin aspart is indicated to improve glycemic control in adults and children with diabetes mellitus.
- Associated Conditions
- Diabetes Mellitus, Diabetic Ketoacidosis, Gestational Diabetes Mellitus (GDM), Hyperglycemia during critical illness
- Associated Therapies
- -
Diluted Insulin in Young Children: Bigger Volumes for Smaller Patients
- First Posted Date
- 2018-09-11
- Last Posted Date
- 2023-08-14
- Lead Sponsor
- Yale University
- Target Recruit Count
- 3
- Registration Number
- NCT03666065
- Locations
- 🇺🇸
Yale University School of Medicine, New Haven, Connecticut, United States
Simplified Insulin Regimen for the Elderly
- Conditions
- Interventions
- First Posted Date
- 2018-09-06
- Last Posted Date
- 2023-12-12
- Lead Sponsor
- University of Miami
- Target Recruit Count
- 7
- Registration Number
- NCT03660553
- Locations
- 🇺🇸
University of Miami, South Miami, Florida, United States
Comparison of FiAsp and Aspart During Postprandial Exercise in Adults With Type 1 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2018-09-06
- Last Posted Date
- 2023-09-01
- Lead Sponsor
- Institut de Recherches Cliniques de Montreal
- Target Recruit Count
- 40
- Registration Number
- NCT03659799
- Locations
- 🇨🇦
Institut de recherches cliniques de Montréal, Montréal, Quebec, Canada
Evaluation of Fiasp® (Fast Acting Insulin Aspart) in 670G Hybrid Closed-Loop Therapy
- First Posted Date
- 2018-06-13
- Last Posted Date
- 2021-08-18
- Lead Sponsor
- Stanford University
- Target Recruit Count
- 27
- Registration Number
- NCT03554486
- Locations
- 🇺🇸
Stanford University, Palo Alto, California, United States
🇺🇸Stanford, Palo Alto, California, United States
Use of NPH Versus Basal Bolus Insulin for Steroid Induced Hyperglycemia
- Conditions
- Interventions
- First Posted Date
- 2018-04-27
- Last Posted Date
- 2020-09-11
- Lead Sponsor
- Northwestern University
- Target Recruit Count
- 3
- Registration Number
- NCT03511521
- Locations
- 🇺🇸
Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States
A Meal Test Study of LY900014 in Participants With Type 1 Diabetes Mellitus
- Conditions
- Interventions
- First Posted Date
- 2018-02-28
- Last Posted Date
- 2020-04-30
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 80
- Registration Number
- NCT03449433
- Locations
- 🇩🇪
Profil Institut für Stoffwechselforschung, Neuss, Nordrhein-Westfalen, Germany
Safety Assessment of SAR341402 and NovoLog® Used in Continuous Subcutaneous Insulin Infusion for Type 1 Diabetes Mellitus Patients
- Conditions
- Interventions
- First Posted Date
- 2018-02-19
- Last Posted Date
- 2022-04-25
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 45
- Registration Number
- NCT03436498
- Locations
- 🇺🇸
Investigational Site Number 8400001, Little Rock, Arkansas, United States
🇺🇸Investigational Site Number 8400002, Denver, Colorado, United States
🇺🇸Investigational Site Number 8400003, West Des Moines, Iowa, United States
Comparison of Insulin Tregopil (IN-105) With Insulin Aspart in Type 2 Diabetes Mellitus Patients
- Conditions
- Interventions
- First Posted Date
- 2018-02-13
- Last Posted Date
- 2020-05-15
- Lead Sponsor
- Biocon Limited
- Target Recruit Count
- 143
- Registration Number
- NCT03430856
- Locations
- 🇮🇳
Diacon Hospital, Bangalore, Karnataka, India
Research Study Comparing Insulin Degludec to Insulin Detemir, Together With Insulin Aspart, in Pregnant Women With Type 1 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2017-12-19
- Last Posted Date
- 2023-01-20
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 225
- Registration Number
- NCT03377699
- Locations
- 🇬🇧
Novo Nordisk Investigational Site, Truro, United Kingdom
Insulin Degludec and Glargine U100 for Management of Hospitalized and Discharged Patients With Type 2 Diabetes
- First Posted Date
- 2017-11-08
- Last Posted Date
- 2022-03-31
- Lead Sponsor
- Emory University
- Target Recruit Count
- 180
- Registration Number
- NCT03336528
- Locations
- 🇺🇸
Emory University Hospital Clinical Research Network, Atlanta, Georgia, United States
🇺🇸Grady Hospital, Atlanta, Georgia, United States
🇺🇸Mount Sinai, New York, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.